This article was originally published in The Gray Sheet
Diagnostics developer raises $30 mil. from Swartz Private Equity, LLC, to be drawn by Lexon as needed over the next three years. Tulsa, Oklahoma-based Lexon, which owns the exclusive worldwide rights to the Ebaf Assay blood test to screen for colon cancer and the Telomerase Assay blood test to screen for lung cancer, will use the funds for "ongoing product development and initiation of FDA clinical trials," the firm states in an Aug. 21 release. Current development efforts "are focused on expanding the battery of monoclonal antibodies for each test, producing prototype blood screening test kits, performing multiple blood tests on known cancer patients, and statistically evaluating test results for presentation to the FDA," Lexon reports
You may also be interested in...
Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.